DPP4 and metastatic neoplasm: Nazarian et al. found that DPP4 was reduced in mice with progressive invasive prostate cancer, and DPP4 activity could be used alone or in combination, the latter being more likely, with other markers of prostate cancer as an indicator of metastatic disease [33].